Market Overview

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Related BMY
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Drug Giants Advance Cancer Treatments (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Bristol-Myers Squibb Co. closed on Thursday at $46.17.

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters